Needham & Company LLC reaffirmed their buy rating on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a research note released on Friday, Benzinga reports. Needham & Company LLC currently has a $23.00 target price on the stock.
A number of other research analysts also recently issued reports on INZY. Jefferies Financial Group restated a “buy” rating and set a $17.00 price target (up previously from $16.00) on shares of Inozyme Pharma in a research note on Tuesday, August 13th. Wedbush reiterated an “outperform” rating and issued a $15.00 target price on shares of Inozyme Pharma in a research note on Monday, September 30th. HC Wainwright reiterated a “buy” rating and issued a $14.00 target price on shares of Inozyme Pharma in a research note on Thursday, August 8th. Finally, Stifel Nicolaus started coverage on Inozyme Pharma in a research note on Thursday, September 12th. They issued a “buy” rating and a $16.00 target price on the stock. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Inozyme Pharma currently has a consensus rating of “Buy” and an average target price of $16.14.
Read Our Latest Stock Report on INZY
Inozyme Pharma Trading Down 0.2 %
Inozyme Pharma (NASDAQ:INZY – Get Free Report) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.07). On average, research analysts anticipate that Inozyme Pharma will post -1.68 EPS for the current year.
Institutional Trading of Inozyme Pharma
A number of institutional investors have recently modified their holdings of INZY. Vanguard Group Inc. boosted its stake in shares of Inozyme Pharma by 1.4% in the first quarter. Vanguard Group Inc. now owns 2,419,020 shares of the company’s stock valued at $18,530,000 after buying an additional 33,998 shares in the last quarter. Affinity Asset Advisors LLC raised its holdings in Inozyme Pharma by 40.1% during the first quarter. Affinity Asset Advisors LLC now owns 2,642,519 shares of the company’s stock worth $20,242,000 after purchasing an additional 756,717 shares during the last quarter. Kennedy Capital Management LLC raised its holdings in Inozyme Pharma by 52.2% during the first quarter. Kennedy Capital Management LLC now owns 437,657 shares of the company’s stock worth $3,352,000 after purchasing an additional 150,120 shares during the last quarter. Values First Advisors Inc. acquired a new position in Inozyme Pharma during the second quarter worth $76,000. Finally, Bank of New York Mellon Corp raised its holdings in shares of Inozyme Pharma by 16.1% in the second quarter. Bank of New York Mellon Corp now owns 190,896 shares of the company’s stock worth $851,000 after acquiring an additional 26,464 shares during the last quarter. 88.30% of the stock is currently owned by hedge funds and other institutional investors.
About Inozyme Pharma
Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.
Featured Articles
- Five stocks we like better than Inozyme Pharma
- Canadian Penny Stocks: Can They Make You Rich?
- Inflation Risk Rising, Key Trades Investors Are Making Now
- Pros And Cons Of Monthly Dividend Stocks
- 3 Oil Stocks to Watch Before Earnings Come Out
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
Receive News & Ratings for Inozyme Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inozyme Pharma and related companies with MarketBeat.com's FREE daily email newsletter.